{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T16:25:34Z","timestamp":1790526334514,"version":"4.1.0"},"reference-count":30,"publisher":"Impact Journals, LLC","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2015,4,20]]},"DOI":"10.18632\/oncotarget.3275","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T07:00:46Z","timestamp":1442300446000},"page":"8750-8759","source":"Crossref","is-referenced-by-count":74,"title":["Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma"],"prefix":"10.18632","volume":"6","author":[{"given":"David","family":"Chiron","sequence":"first","affiliation":[{"name":"INSERM, UMR892 - CNRS, UMR 6299, Universit\u00e9 de Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Dousset","sequence":"additional","affiliation":[{"name":"INSERM, UMR892 - CNRS, UMR 6299, Universit\u00e9 de Nantes, France"},{"name":"Service d\u2019H\u00e9matologie Clinique, Unit\u00e9 d\u2019Investigation Clinique, Centre Hospitalier Universitaire de Nantes, France"},{"name":"CIC, INSERM, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Brosseau","sequence":"additional","affiliation":[{"name":"INSERM, UMR892 - CNRS, UMR 6299, Universit\u00e9 de Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Touzeau","sequence":"additional","affiliation":[{"name":"INSERM, UMR892 - CNRS, UMR 6299, Universit\u00e9 de Nantes, France"},{"name":"Service d\u2019H\u00e9matologie Clinique, Unit\u00e9 d\u2019Investigation Clinique, Centre Hospitalier Universitaire de Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Ma\u00efga","sequence":"additional","affiliation":[{"name":"INSERM, UMR892 - CNRS, UMR 6299, Universit\u00e9 de Nantes, France"},{"name":"Service d\u2019H\u00e9matologie Clinique, Unit\u00e9 d\u2019Investigation Clinique, Centre Hospitalier Universitaire de Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[{"name":"INSERM, UMR892 - CNRS, UMR 6299, Universit\u00e9 de Nantes, France"},{"name":"Service d\u2019H\u00e9matologie Clinique, Unit\u00e9 d\u2019Investigation Clinique, Centre Hospitalier Universitaire de Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Pellat-Deceunynck","sequence":"additional","affiliation":[{"name":"INSERM, UMR892 - CNRS, UMR 6299, Universit\u00e9 de Nantes, France"},{"name":"Service d\u2019H\u00e9matologie Clinique, Unit\u00e9 d\u2019Investigation Clinique, Centre Hospitalier Universitaire de Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Le Gouill","sequence":"additional","affiliation":[{"name":"INSERM, UMR892 - CNRS, UMR 6299, Universit\u00e9 de Nantes, France"},{"name":"Service d\u2019H\u00e9matologie Clinique, Unit\u00e9 d\u2019Investigation Clinique, Centre Hospitalier Universitaire de Nantes, France"},{"name":"CIC, INSERM, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Amiot","sequence":"additional","affiliation":[{"name":"INSERM, UMR892 - CNRS, UMR 6299, Universit\u00e9 de Nantes, France"},{"name":"Service d\u2019H\u00e9matologie Clinique, Unit\u00e9 d\u2019Investigation Clinique, Centre Hospitalier Universitaire de Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2015,3,5]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3109\/10428194.2012.733882","article-title":"Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network","volume":"54","author":"Visco","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"2","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Tilly","year":"2012","journal-title":"N Engl J Med"},{"key":"3","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1172\/JCI61272","article-title":"Molecular pathogenesis of mantle cell lymphoma","volume":"122","author":"Campo","year":"2012","journal-title":"J Clin Invest"},{"key":"4","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1182\/blood-2008-07-170183","article-title":"Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling","volume":"113","author":"Campo","year":"2009","journal-title":"Blood"},{"key":"5","first-page":"4398","article-title":"Mantle Cell Lymphomas Express a Distinct Genetic Signature Affecting Lymphocyte Trafficking and Growth Regulation as Compared with Subpopulations of Normal Human B Cells","volume":"62","author":"Borrebaeck","year":"2002","journal-title":"Cancer Res"},{"key":"6","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1182\/blood.V98.3.787","article-title":"Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray","volume":"98","author":"Koeffler","year":"2001","journal-title":"Blood"},{"key":"7","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ccr.2007.07.001","article-title":"BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents","volume":"12","author":"Letai","year":"2007","journal-title":"Cancer Cell"},{"key":"8","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Elmore","year":"2008","journal-title":"Cancer Res"},{"key":"9","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease","volume":"30","author":"McKeegan","year":"2012","journal-title":"J Clin Oncol"},{"key":"10","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Hymowitz","year":"2013","journal-title":"Nat Med"},{"key":"11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ccr.2013.01.018","article-title":"ABT-199: Taking Dead Aim at BCL-2","volume":"23","author":"Letai","year":"2013","journal-title":"Cancer Cell"},{"key":"12","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.semcancer.2011.09.006","article-title":"The microenvironment in mantle cell lymphoma: cellular and molecular pathways and emerging targeted therapies","volume":"21","author":"Ford","year":"2011","journal-title":"Semin Cancer Biol"},{"key":"13","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1182\/blood-2008-10-185827","article-title":"Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting","volume":"113","author":"Burger","year":"2009","journal-title":"Blood"},{"key":"14","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/1078-0432.CCR-11-1440","article-title":"Tipping the Noxa\/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia","volume":"18","author":"Eldering","year":"2012","journal-title":"Clin Cancer Res"},{"key":"15","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1182\/blood-2008-08-173310","article-title":"Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia","volume":"113","author":"Cohen","year":"2009","journal-title":"Blood"},{"key":"16","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1182\/blood-2012-02-414060","article-title":"Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia","volume":"120","author":"Letai","year":"2012","journal-title":"Blood"},{"key":"17","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Buggy","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"18","doi-asserted-by":"crossref","first-page":"5973","DOI":"10.1158\/1078-0432.CCR-11-0955","article-title":"ABT-737 Induces Apoptosis in Mantle Cell Lymphoma Cells with a Bcl-2 high\/Mcl-1low Profile and Synergizes with Other Antineoplastic Agents","volume":"17","author":"Le Gouill","year":"2011","journal-title":"Clin Cancer Res"},{"key":"19","doi-asserted-by":"crossref","first-page":"5375","DOI":"10.1093\/emboj\/cdf542","article-title":"CD40 regulates the processing of NF-kappaB2 p100 to p52","volume":"21","author":"Ley","year":"2002","journal-title":"EMBO J"},{"key":"20","doi-asserted-by":"crossref","first-page":"9136","DOI":"10.1073\/pnas.96.16.9136","article-title":"NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1\/A1 is required for CD40 survival signaling in B lymphocytes","volume":"96","author":"Cheng","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"21","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Radford","year":"2013","journal-title":"N Engl J Med"},{"key":"22","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1182\/blood-2013-02-482125","article-title":"Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients","volume":"122","author":"Spaargaren","year":"2013","journal-title":"Blood"},{"key":"23","doi-asserted-by":"crossref","first-page":"9033","DOI":"10.18632\/oncotarget.1925","article-title":"The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors","volume":"5","author":"Ong","year":"2014","journal-title":"Oncotarget"},{"key":"24","first-page":"pii","article-title":"ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia","author":"Benoit","year":"2014","journal-title":"Blood"},{"key":"25","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1182\/blood-2014-03-560284","article-title":"Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma","volume":"123","author":"Martinez-Climent","year":"2014","journal-title":"Blood"},{"key":"26","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.1182\/blood-2008-03-146704","article-title":"c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches","volume":"112","author":"Eldering","year":"2008","journal-title":"Blood"},{"key":"27","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/MOH.0000000000000057","article-title":"Do mantle cell lymphomas have an \u201cAchilles heel\u201d?","volume":"21","author":"Wiestner","year":"2014","journal-title":"Curr Opin Hematol"},{"key":"28","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","article-title":"Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C81S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma","volume":"4","author":"Ely","year":"2014","journal-title":"Cancer Discov"},{"key":"29","article-title":"Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT, and BCL2 pathways","author":"Hsi","year":"2014","journal-title":"Br J Haematol"},{"key":"30","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1038\/bjc.2013.186","article-title":"Paradoxical effect of lenalidomide on cytokine\/growth factor profiles in multiple myeloma","volume":"108","author":"Amiot","year":"2013","journal-title":"Br J Cancer"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.3275","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T09:33:56Z","timestamp":1599557636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.3275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,5]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,4,20]]}},"alternative-id":["3275","25797245"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.3275","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,5]]}}}